Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been given a consensus recommendation of “Hold” by the five research firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $13.75.

Several equities research analysts recently commented on the company. Leerink Partners cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their price target for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. TD Cowen reduced their price target on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Leerink Partnrs cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Monday, September 16th.

Insider Buying and Selling

In related news, major shareholder Eli Samaha purchased 999,800 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was acquired at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the transaction, the insider now directly owns 9,511,150 shares in the company, valued at approximately $74,186,970. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TBPH. Hsbc Holdings PLC acquired a new position in Theravance Biopharma during the 2nd quarter worth $108,000. Ballentine Partners LLC purchased a new stake in Theravance Biopharma during the 3rd quarter worth about $104,000. XTX Topco Ltd purchased a new stake in Theravance Biopharma during the 2nd quarter worth about $129,000. State Board of Administration of Florida Retirement System boosted its position in shares of Theravance Biopharma by 28.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 4,990 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Theravance Biopharma by 30.7% in the 1st quarter. BNP Paribas Financial Markets now owns 33,458 shares of the biopharmaceutical company’s stock valued at $300,000 after acquiring an additional 7,851 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Up 0.1 %

Shares of TBPH opened at $8.64 on Friday. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $11.71. The stock has a market cap of $420.19 million, a PE ratio of -10.05 and a beta of 0.25. The firm’s fifty day moving average is $8.21 and its two-hundred day moving average is $8.76.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). The business had revenue of $14.26 million for the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. As a group, research analysts anticipate that Theravance Biopharma will post -1.04 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.